site stats

Thor-707 sitc

WebJul 5, 2024 · THOR-707 Q3W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W will consist of one 9-week cycle of THOR monotherapy … WebJul 5, 2024 · THOR-707 Q3W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W will consist of one 9-week cycle of THOR monotherapy on Cycle 1 Day 1 followed by THOR-707 Q3W + checkpoint inhibitor at Cycle 1 Day 22. Subsequently treatment will consist of repeated 6-weeks cycles with combination therapy.

THOR-707, a novel not-alpha IL-2, promotes all key immune …

WebJun 27, 2024 · THOR-707 Q3W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W will consist of one 9-week cycle of THOR monotherapy on Cycle 1 Day 1 followed by THOR-707 Q3W + checkpoint inhibitor at Cycle 1 Day 22. Subsequently treatment will consist of repeated 6-weeks cycles with combination therapy. WebOct 1, 2024 · While this is a reasonable strategy to avoid off-tumor side effects, clinical benefit has been seen with multiple untargeted IL-2 variant molecules such as NKTR-214, THOR-707, and ALKS-4230 23, 24 ... hinchcliffe landscaping https://getmovingwithlynn.com

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in …

WebApr 9, 2024 · In pre-clinical experiments, THOR-707 exhibited the ability to induce the expansion of CD8+T-cells suggesting potential for anti-tumor effects both as single agent … WebMay 26, 2024 · Methods: Using a synthetic biology platform, we have engineered THOR-707, a rIL-2 that contains a novel amino acid encoded in the IL-2 gene via a new DNA base pair (X-Y). The novel amino acid serves as a hook for site specific pegylation that extends half-life, blocks IL-2R⍺ engagement and binds to the IL-2Rβγ. WebImage for SITC 2024: Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in Combination with a PD-1 Inhibitor in Adult … hinchcliffe indy racer accident 2017

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in …

Category:SITC 2024: Phase 1/2 study of THOR-707 (SAR444245), a …

Tags:Thor-707 sitc

Thor-707 sitc

Lighting up only the immune cells that matter Asher Bio

WebOct 1, 2024 · THOR-707 is a reprogrammed, site-directed, single pegylated, recombinant human IL-2 (rIL-2) variant that lacks binding affinity for the α chain of the IL-2 receptor. … WebNov 9, 2024 · Synthorx to Present Preclinical Data for THOR-707, a "Not-Alpha" IL-2 Synthorin, for the Treatment of Solid Tumors at SITC 2024 News provided by. Synthorx, …

Thor-707 sitc

Did you know?

WebJun 4, 2024 · A Phase 1/2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR- 707) Combined With Cemiplimab for the Treatment of Participants With Advanced Unresectable or Metastatic Skin Cancers: Actual Study Start Date : July 15, 2024: Estimated Primary Completion Date : August 22, … WebBackground SAR444245 (THOR-707) is a recombinant human IL-2 molecule that includes a PEG moiety irreversibly bound to a novel amino acid via click chemistry to block the alpha …

WebNov 3, 2024 · The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other … WebOct 29, 2024 · Part 1 of the study will determine the recommended phase 2 dose (RP2D) of THOR-707 as a single agent and part 2 will determine the RP2D of THOR-707 in combination with a PD-1 inhibitor.

WebNov 1, 2024 · Background THOR-707 (SAR444245) is a recombinant human IL-2 molecule irreversibly bound to a PEG chain to block alpha-binding while retaining near-native affinity … WebJun 7, 2024 · A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Pleural Mesothelioma: Actual Study Start Date : September 23, 2024: Estimated Primary Completion Date : July …

WebOct 1, 2024 · THOR-707 is a reprogrammed, site-directed, single pegylated, recombinant human IL-2 (rIL-2) variant that lacks binding affinity for the α chain of the IL-2 receptor. Because THOR-707 has near-native binding affinity for the βγ chain of the IL-2 receptor, it produces an immune-active, CD8+ T effector-driven anti-tumor effect. hinchcliffe mdWebNov 9, 2024 · Synthorx Inc. announced that company researchers will present results of preclinical studies demonstrating the safety and anti-tumor effects of its lead product candidate THOR-707, a Synthorin of... March 12, 2024 hinchcliffe huddersfieldWebApr 4, 2024 · Latest Information Update: 21 Nov 2024. Price : $50 *. Buy Profile. Adis is an information provider. We do not sell or distribute actual drugs. Final gross price and currency may vary according to local VAT and billing address. Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. hinchcliffe maskWebNov 9, 2024 · SAN DIEGO, Nov. 9, 2024 /PRNewswire/ -- Synthorx, Inc., a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform techn... homeless a human storyWebAug 9, 2024 · The THOR-707 volume of distribution at steady state (Vss; 82.4 mL/kg) was about 4.7-fold reduced relative to aldesleukin and similar to the blood volume for mice 17 … hinchcliffe mill west yorksWebOct 29, 2024 · SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Synthorx, Inc.(NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the presentation of three posters at the upcoming Society for Immunotherapy of Cancer (SITC) 34 th Annual Meeting in National … homeless aid uk press releaseWebImage for SITC 2024: Phase 1/2 study of THOR-707 (SAR444245), a pegylated recombinant non-alpha IL-2, as monotherapy and in combination with pembrolizumab or cetuximab in … hinchcliffe james